The global mycoplasma testing market size was valued at USD 446.9 million in 2016 and is anticipated to witness an attractive growth over the forecast period. Increasing investments in R&D activities have contributed toward significant revenue for mycoplasma testing Industry. With growing healthcare expenditure levels, research activities in life science segment is also rising to a great extent.
Rapid research activities conducted by the pharmaceutical and biotechnology industries are resulting in adoption of new technologies for drug discovery and development. According to the 2016 Global R&D Funding Forecast, there has been a 3.5% increase in R&D investments throughout the world. Moreover, a recent news stated that USD 40.1 billion expenditure had been made by biotech companies in 2015. Thus, a huge amount of spending in R&D activities is expected to enhance developments in this field, thereby boosting the demand for mycoplasma testing products.
U.S. mycoplasma testing market, by product, 2014 - 2025 (USD Million)
Research work for pharmaceutical and biotechnology sectors are being increasingly supported by the government. The U.S. government is providing financial support to the global pharmaceutical companies in order to facilitate research-based activities for new drug development. For instance, in 2013, GlaxoSmithKline entered into an agreement of USD 200 million with the U.S. government to develop antibiotic drugs. Thus, growing government funding for pharmaceutical and biotechnology sector has stimulated R&D activities, thereby, fostering huge application of mycoplasma testing products.
Mycoplasma contamination also adversely affects the research work of scientists in laboratories. Human mycoplasma is a key source of cell culture contamination that occurs due to the laboratories workers who are infected with M. orale or M. fermentans. Mycoplasma contamination can also arise out of a previously infected cell culture that was brought in the laboratory. Hence, testing of such bacteria is considered as a significant requirement to generate a robust data in the field of biomedical research.
On the basis of products, the market is segmented into instruments, kits & reagents, and services. Kits & reagents accounted for the largest market share in 2016 owing to repeated purchase of consumables for detection of mycoplasma in cell culture research work. Kit & reagents are further segmented into PCR assays, nucleic acid detection kits, stains, elimination kits, and standards & controls.
Instruments are expected to showcase significant growth over the forecast period. This is due to the growing availability of automated instruments for the detection mycoplasma, which delivers rapid results with greater efficiency.
On the basis of technology, the PCR segment held the largest market share in 2016. This technology enables the detection of multiple species of mycoplasma while separating other contaminating DNA. It provides test results with high specificity and efficiency.
Microbial culture is expected to showcase attractive growth over the forecast period. This is due to the rising number of research activities conducted in the field of biopharmaceutical industry and huge application of this technology in mycoplasma contamination testing.
On the basis of application, cell line testing contributed toward the largest revenue in 2016 owing to growing number of research activities undertaken in the field of cell culture. It is also expected to witness highest growth over the forecast period due to rising mycoplasma contamination in cell culture.
End of production cells testing is anticipated to exhibit significant growth over the forecast period owing to huge amount of cell harvest and growing number of clinical trials for drug discovery & development. Thus, quality control measures taking place in the process of drug discovery is majorly triggering growth of this segment.
North America mycoplasma testing market share, by application, 2016 (%)
On the basis of end-use, pharmaceutical and biotechnology companies held the largest market share in 2016 due to huge amount of investments made in R&D activities by such companies, which has led to progressive research related to drug discovery.
Contract research organizations are expected to show lucrative growth over the forecast period owing to huge number of research services being conducted by these organizations, which are outsourced by pharmaceutical and biotechnology companies.
In 2016, North America dominated the mycoplasma testing industry owing to rising healthcare spending and investments made by the U.S. government to promote research-based activities in biopharmaceutical industries.
Asia Pacific is projected to display lucrative growth over the forecast period. This is due to significant awareness and funding initiatives generated by the Indian government to facilitate additional R&D activities for the introduction of new drugs.
Some of the significant players of the market include Thermo Fisher Scientific; Merck KGaA; Lonza Group Ltd.; PromoCell GmbH; ATCC (American Type Culture Collection); Charles River Laboratories International, Inc.; Bionique Testing Laboratories, Inc.; Biological Industries Israel Beit Haemek Ltd.; and InvivoGen.
The key strategies concerning the growth of these companies include new product development, mergers & acquisitions, and geographical expansions. For instance, in 2015, Merck acquired Sigma-Aldrich Co., one of the global leaders in life science sector, with an aim to serve customers in the field of life science.
Base year for estimation
Actual estimates/Historical data
2014 - 2015
2017 - 2025
Revenue in USD Million & CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America & MEA
U.S., Canada, UK, Germany, Japan, India, China, Brazil, Mexico, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
Segments Covered in the Report
This report forecasts revenue growth at global, regional, & country levels and provides an analysis on the industry trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the mycoplasma testing market on the basis of product, technology, application, end-use, and region:
Product Outlook (Revenue, USD Million; 2014 - 2025)
Kits & Reagents
Nucleic Acid Detection Kits
Standards & Controls
Technology Outlook (Revenue, USD Million; 2014 - 2025)
Microbial Culture Techniques
Application Outlook (Revenue, USD Million; 2014 - 2025)
Cell Line Testing
End of Production Cells Testing
End-Use Outlook (Revenue, USD Million; 2014 - 2025)
Academic Research Institutes
Contract Research Organizations
Pharmaceutical & Biotechnology Companies
Regional Outlook (Revenue, USD Million; 2014 - 2025)
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.